New medical device regulation: Neuromedex meets the highest standards

We are pleased to inform you that thanks to our proactive measures, our product range falls under the transitional provisions until at least 2027.

We are proud to announce that our product portfolio has already been submitted for MDR approval to a Notified Body. This means a continuous delivery availability even after the transitional provision.

For further information or if you have any questions, please do not hesitate to contact us personally or by email at contact@neuromedex.com.